Cell Surface Notch Ligand DLL3 is a Therapeutic Target in Isocitrate Dehydrogenase-mutant Glioma.
Marissa SpinoSylvia C KurzLuis A ChiribogaJonathan SerranoBriana ZeckNamita SenSeema PatelGuomiao ShenVarshini VasudevarajaAristotelis TsirigosCarter M SuryadevaraJoshua D FrensterKensuke TateishiHiroaki WakimotoRajan JainHoward A RiinaTheodore P NicolaidesErik P SulmanDaniel P CahillJohn G GolfinosKumiko IsseLaura R SaundersDavid ZagzagDimitris G PlacantonakisMatija SnuderlAndrew S ChiPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2018)
DLL3 is selectively and homogeneously expressed in IDH-mutant gliomas and can be targeted with Rova-T in patient-derived IDH-mutant glioma tumorspheres. Our findings are potentially immediately translatable and have implications for therapeutic strategies that exploit cell surface tumor-associated antigens.